Furthermore, we provide evidence of why potent VEGF-C-based therapy alone is unlikely to be therapeutically beneficial in reversing the radiation-induced injury to LEC and the lymphatics that they constitute, and therefore, also in treating the resulting condition of lymphoedema in patients that have undergone surgery and radiation therapy to treat their cancer. This evidence concerns the gene VEGFC and lymphedema.